SUBSCRIPTION AGREEMENTSubscription Agreement • January 2nd, 2020 • Quadrant Biosciences Inc • Pharmaceutical preparations • New York
THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES, AND NO PUBLIC MARKET IS EXPECTED TO DEVELOP FOLLOWING THIS OFFERING.
Broker-Dealer AgreementBroker-Dealer Agreement • January 2nd, 2020 • Quadrant Biosciences Inc • Pharmaceutical preparations
This Broker-Dealer Agreement (together with exhibits, this “Agreement”) is entered into by and between Quadrant Biosciences, Inc., a Delaware Corporation (“Client”), and North Capital Private Securities Corporation, a Delaware Corporation (“North Capital”). Client and North Capital agree to be bound by the terms of this Agreement, effective as of December 13, 2019 (the “Effective Date”).
QUADRANT BIOSCIENCES INC. AMENDED AND RESTATED STOCKHOLDERS AGREEMENTStockholders Agreement • January 2nd, 2020 • Quadrant Biosciences Inc • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”) is made and entered into as of this 5th day of March, 2018, by and among QUADRANT BIOSCIENCES INC., a Delaware corporation (the “Company”), and each of the Persons and entities listed on Exhibit A hereto as amended from time to time (the “Stockholders”). Unless otherwise specified in this Agreement, capitalized terms used herein shall have the meanings set forth in Section 1.2 of this Agreement.
